Vaxart reports FY2025 net income of $16.3M vs loss; revenue $237.3M; cash runway into Q2 2027

Vaxart, Inc.

Net income $16.3M ($0.07 EPS) vs net loss $66.9M ($0.33 loss) in FY2024.
Revenue $237.3M, up from $28.7M, driven by BARDA contract and Dynavax collaboration.
Cash, equivalents & investments $63.8M; runway into Q2 2027.
COVID-19 Phase 2b sentinel cohort data (400 subjects) expected early Q2 2026; main cohort topline Q4 2026.
Published Phase 1 norovirus data shows passive antibody transfer to infants via breast milk; next trial dependent on partnership.

Key facts

Extracted from this filing and checked against the source text.

Earnings Releases SEC 8-K Item 2.02 confidence 0.9

Vaxart, Inc. reported the full year ended December 31, 2025 results: revenue $237.3 million, net income $16.3 million, EPS $0.07.

Period: the full year ended December 31, 2025
Revenue: $237.3 million
Net income: $16.3 million
EPS: $0.07
Result: reported results

Exact text from the filing

non-dilutive funding options, with the goal of achieving its upcoming clinical and regulatory milestones and maximizing stockholder value. ● Revenue for the full year 2025 was $237.3 million, compared to $28.7 million for the full year 2024. Revenue in the full year 2025 and the full year 2024 was primarily from government contracts related to the BARDA contract

View on SEC.gov

Browse all earnings releases →

Vaxart, Inc. filing history →

Source: SEC EDGAR

accession 0001437749-26-007968

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.